Developer docs
API playgroundTry for free, no card

Search company profiles

Ocumeda

Full company profile

uuid0003m67

Namestring
Ocumeda
Legal namestring
ocumeda GmbH
Websiteurl
ocumeda.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Ocumeda, founded in 2019 in Canton Thurgau, Switzerland, and headquartered in Munich as ocumeda GmbH, operates a cloud-based teleophthalmology platform that connects certified partner opticians with a network of 35+ tele-ophthalmologists across Germany, Austria and Switzerland. Its flagship service, the Augen-Check-Up, combines in-store measurements (visual acuity, refraction, intraocular pressure via tonometer, fundus photography) at optical retail locations with remote specialist interpretation, delivering a colour-coded traffic-light result within 48 hours. The platform powers three product modules: the standard Augen-Check-Up, Augen-Check-Up Plus (which adds anterior segment imaging), and the Ocumeda Care Network for structured referrals to local ophthalmologists.

The business model is primarily B2B2C, charging optician partners a per-screening fee for each Augen-Check-Up performed and earning enterprise platform fees from strategic partners Fielmann Group and ZEISS Vision Care (which also embedded Ocumeda as the medical layer of its ZEISS EyeCare Network). Revenue is supplemented by insurance reimbursement flows in Switzerland (KPT covers up to 75% of the cost for Pulse policyholders; CSS covers from 2023). The company serves consumer end-users (predominantly 40+ demographic) seeking accessible preventive eye screening, optical retail chains and independent opticians seeking a medically validated upsell service, and ophthalmologists who gain asynchronous review capacity.

Ocumeda operates through 800+ partner optician locations across the DACH region and has completed more than 500,000 screenings, detecting 110,000+ abnormalities and 3,500+ urgent cases. It is backed by Fielmann Group and ZEISS Vision Care (which acquired a 10% stake at a €100 million valuation in October 2025). The company holds ISO 13485 certification, is GDPR-compliant with ISO/IEC 27001 and BSI C5 cloud infrastructure, and is undergoing a €600,000 UKE Hamburg clinical validation study funded by Fielmann.

Short descriptiontext

Ocumeda operates a cloud teleophthalmology platform connecting 800+ DACH partner opticians with 35+ remote ophthalmologists to deliver the Augen-Check-Up, a low-threshold preventive eye screening service powered by Fielmann and ZEISS distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMünchen, Germany
HQ citystring
München
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
teleophthalmology platform, preventive eye screening, medical eye examinations, retinal image analysis, optical retail services
Industry3 codes
PRIMARYHLALAGAL
Ophthalmology & Vision Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLAKAKAB
Optometry Clinics (Primary Eye Care)
NAICS code1 code
  • Offices of Optometrists62132
Product category
Teleophthalmology / Preventive Eye Care Screening
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Per-Screening Fees (B2B to Opticians)
TypeTransaction Fee
Description

Ocumeda charges optician partners (optical retail chains and independent stores) a fee for each Augen-Check-Up conducted using the Ocumeda platform. The screening data is collected by trained optician staff and transmitted to Ocumeda's tele-ophthalmologist network for interpretation. Revenue is generated on a per-transaction basis per screening performed.

ocumeda.com
2Insurance Reimbursement (Switzerland)
TypeTransaction Fee
Description

In Switzerland, the Ocumeda Augen-Check-Up is covered by health insurance KPT for patients with Pulse Top or Pulse Premium supplementary insurance (up to 75% cost reimbursement). This creates a reimbursement revenue stream alongside the consumer self-pay model, reducing patient out-of-pocket cost.

ocumeda.com
3B2B Enterprise Platform Licensing
TypeSubscription Recurring
Description

Ocumeda provides its teleophthalmology platform to enterprise customers such as ZEISS Vision Care (ZEISS EyeCare Network) and Fielmann Group, where Ocumeda acts as the underlying medical infrastructure. Revenue is derived from platform licensing and per-screening arrangements with these enterprise partners.

ocumeda.com
4Premium Screening Upgrades (Augen-Check-Up Plus)
TypeTransaction Fee
Description

The extended Augen-Check-Up Plus (adding anterior eye segment imaging) represents an upsell opportunity over the standard screening, allowing opticians to offer a more comprehensive premium service at a higher price point.

ocumeda.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Standard Augen-Check-Up (KPT Reimbursement in Switzerland)
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

In Switzerland, KPT insurance covers up to 75% of the Augen-Check-Up cost for patients with Pulse Top or Pulse Premium supplementary insurance. Patients with standard insurance pay out-of-pocket. Available at ~50 Optiker-Standorten in Switzerland.

ocumeda.com
2Standard Augen-Check-Up (Self-Pay / Optician-Sold)
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

The Augen-Check-Up is a self-pay consumer service. Opticians set their own pricing under a recommended retail price from ZEISS (for ZEISS EyeCare Network). No free trial or freemium model is described.

ocumeda.com
3Augen-Check-Up Plus (Extended Screening)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

The extended Augen-Check-Up Plus (anterior eye segment imaging) is an optional upgrade to the standard check-up, offered at a premium price point determined by each optician partner.

ocumeda.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Ocumeda Augen-Check-Up
Description

The core teleophthalmological eye screening service offered at partner opticians, involving measurements of visual acuity, refraction, intraocular pressure, and fundus photography, analyzed by ophthalmologists.

ocumeda.com
+3 more records
Core offering1 text field

Ocumeda operates a cloud-based teleophthalmology platform that connects trained partner opticians with a network of certified remote ophthalmologists to deliver low-threshold preventive eye screenings. The core Augen-Check-Up service captures fundus photography, intraocular pressure, visual acuity and refraction data at optical retail locations and transmits it for physician interpretation, with results delivered to patients within 48 hours via a traffic-light reporting system. Extended offerings include anterior segment imaging (Augen-Check-Up Plus), structured ophthalmologist referrals (Care Network), and partner optician enablement (Empower).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 110,000 abnormalities detected from 500,000 screenings (~22% detection rate)
+4 more records
Product overview1 text field

Ocumeda operates a modular teleophthalmology platform centered on the Augen-Check-Up, a preventive eye screening service that connects partner opticians with remote ophthalmologists. The core Augen-Check-Up performs fundus photography, intraocular pressure measurement, and visual acuity testing, evaluated by a network of 35 tele-ophthalmologists. Three add-on modules extend the platform: Augen-Check-Up Plus adds anterior segment imaging for a broader anatomical assessment; Ocumeda Care Network facilitates structured referrals to local ophthalmologists for patients with abnormal findings; and Ocumeda Empower provides training, marketing, and consulting to strengthen partner opticians' preventive care capabilities. The platform is available at over 800 partner optician locations across Germany, Austria, and Switzerland.

Product and service5 records
1Augen-Check-Up (Eye Check-Up)
CategoryTeleophthalmology screening service
Description

The flagship teleophthalmology screening service that enables partner opticians to perform preventive eye health checks using fundus photography, intraocular pressure measurement, and visual acuity testing, with remote evaluation by licensed ophthalmologists from Germany, Austria, and Switzerland. Results are delivered to patients within 48 hours via a colour-coded traffic-light reporting system.

2Augen-Check-Up Plus
CategoryTeleophthalmology screening service (extended)
Description

An enhanced version of the standard Augen-Check-Up that additionally captures and evaluates the anterior segment of the eye (eyelids, conjunctiva, cornea, iris, lens), enabling a broader medical screening alongside the existing fundus and intraocular pressure assessment.

3Ocumeda Care Network
CategoryCare coordination platform
Description

A care coordination platform that connects eye check-up participants with abnormal findings to nearby ophthalmologists, enabling opticians to integrate local eye doctor partnerships into their service offering and facilitating structured patient referral and follow-up.

4Ocumeda Empower
CategoryPartner enablement program
Description

A partner support program providing opticians with training (Ocumeda Academy), marketing assets, automated customer re-invitation tools, and consulting to help them establish and grow their preventive eye health service offering.

5ZEISS EyeCare Network (Ocumeda-powered platform)
CategoryEnterprise teleophthalmology platform (white-label)
Description

White-label teleophthalmology platform embedded in the ZEISS EyeCare Network, connecting ZEISS partner opticians (using ZEISS VISUREF 1000 devices) with the Ocumeda tele-ophthalmologist network for preventive eye health checks.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1KPT (Swiss Health Insurance)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

KPT, one of the ten largest Swiss health insurers (~500,000 policyholders), added the Ocumeda Augen-Check-Up to its supplementary insurance (Pulse) benefit list under 'Früherkennung und Diagnostik'. Patients with Pulse Top or Pulse Premium coverage receive up to 75% cost reimbursement. Available at ~50 Ocumeda locations in Switzerland.

ocumeda.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

UKE is conducting a €600,000 medical study (funded by Fielmann Group) to scientifically validate the Ocumeda-based eye check-up screening service. The study compares screening results from Fielmann locations in Hamburg metropolitan area with comprehensive examinations at UKE. Results expected end of 2027. Led by Prof. Dr. Martin Spitzer, Director of the UKE Eye Clinic.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-31
Description

Ocumeda serves as the medical platform powering the ZEISS EyeCare Network. ZEISS Vision Care distributes Ocumeda's Augen-Check-Up to its partner opticians using ZEISS VISUREF 1000 devices. The platform connects optical retail stores with ophthalmologists for preventive eye health checks. Launched in Germany March 2025; Austria and Switzerland in H2 2025. Uses a traffic-light system to flag findings related to diabetic retinopathy, AMD and glaucoma.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-18
Description

Strategic partnership to offer the Ocumeda Augen-Check-Up at Fielmann branches across Germany and Switzerland. Following a successful pilot phase, the service was rolled out to 100+ Fielmann locations by end of 2023, and has since expanded to all Fielmann branches in Germany, Austria and Switzerland. Over 300,000 Fielmann customers have used the service. Fielmann co-funded a €600,000 clinical validation study at UKE.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

CSS, one of the largest Swiss health insurers, began covering Ocumeda Augen-Check-Up costs for its policyholders starting in 2023. This partnership made Ocumeda's screening service accessible through health insurance reimbursement in Switzerland, prior to the KPT partnership.

Strategic tierMinorTypeOthers
Description

UnternehmerTUM, Germany's largest centre for business and innovation, is listed as a partner and supporter of Ocumeda. The nature of the partnership is not explicitly detailed beyond the logo placement on Ocumeda's website.

7ACTO e.V. (Aachener Centrum für Technologietransfer in der Ophthalmologie)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ocumeda developed its concept in collaboration with ACTO e.V. and leading German ophthalmologists. ACTO co-authored the scientific whitepaper (Weißbuch) describing the clinical and scientific background of the Ocumeda Augen-Check-Up.

ocumeda.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Israel-based AI company developing FDA-cleared autonomous screening for diabetic retinopathy and other retinal diseases from fundus photography. Comparable to Ocumeda as a younger AI teleophthalmology competitor targeting optometry and primary care workflows.

TypeBroad incumbent
Description

Germany-based ophthalmic diagnostic imaging company (Heidelberg Retina Tomograph, SPECTRALIS OCT) widely used in clinical ophthalmology. Comparable as a domestic German incumbent in ophthalmic diagnostic imaging whose installed base represents both a potential integration partner and a potential competitor moving toward AI-enabled screening.

TypeBroad incumbent
Description

UK-based (now part of Nikon) ultra-widefield retinal imaging company whose devices are deployed in optometry and ophthalmology practices globally. Comparable as an incumbent retinal imaging hardware vendor relevant to Ocumeda's screening workflow and as a potential vertical competitor in AI-enhanced screening.

TypeDirect peer
Description

US-based developer of the EyeArt AI system for autonomous detection of diabetic retinopathy from fundus images, used in primary care and optometry settings. Closely comparable to Ocumeda's AI-assisted teleophthalmology screening model, though Eyenuk focuses on a single disease (DR) and US regulatory pathway (FDA-cleared).

5Smart Optometry
TypeDirect peer
Description

Slovenia-based developer of mobile eye-screening applications used by optometrists and ophthalmologists for visual acuity, contrast, color vision and basic functional tests. Comparable as a peer in optometry-facing digital screening tools, though with a software/app-only model rather than a full teleophthalmology service.

TypeBroad incumbent
Description

Japan-headquartered global ophthalmic device and software company producing fundus cameras, OCT, and clinical data management systems used in teleophthalmology workflows. Comparable as a vertically integrated incumbent supplying both the imaging hardware (similar to ZEISS VISUREF 1000) and software infrastructure that Ocumeda integrates with.

7Digital Diagnostics
TypeDirect peer
Description

US company (formerly IDx) that pioneered FDA-authorized autonomous AI diagnostic systems (IDx-DR) for diabetic retinopathy screening at point-of-care. Comparable as a direct AI teleophthalmology competitor with regulatory clearance and a similar optometry/primary-care distribution thesis.

TypeEmerging player
Description

Switzerland-based AI health-tech company building ophthalmology data management and AI image analysis tools (RetinAI Discovery, Discovery AIR) used by clinics and pharma. Comparable to Ocumeda as a fellow Swiss-based AI-ophthalmology player addressing disease detection from retinal imaging, though RetinAI is more B2B/research-oriented.

9Doctolib
TypeRegional player
Description

France/Germany-headquartered leading European telehealth and practice-management platform with a strong German user base. Comparable as a broader European digital-health player operating in the same DACH regulatory and reimbursement environment, though Doctolib focuses on appointment booking and video consultations rather than teleophthalmology specifically.

TypeDirect peer
Description

US-based online vision test platform enabling refractive prescription renewal via remote optometrist review. Comparable as a tele-optometry screening service routed through digital channels, though US-focused and oriented to prescription renewal rather than disease detection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ocumeda

Teleophthalmology / Preventive Eye Care Screeningocumeda.com

Ocumeda operates a cloud teleophthalmology platform connecting 800+ DACH partner opticians with 35+ remote ophthalmologists to deliver the Augen-Check-Up, a low-threshold preventive eye screening service powered by Fielmann and ZEISS distribution.

What Ocumeda does

Ocumeda, founded in 2019 in Canton Thurgau, Switzerland, and headquartered in Munich as ocumeda GmbH, operates a cloud-based teleophthalmology platform that connects certified partner opticians with a network of 35+ tele-ophthalmologists across Germany, Austria and Switzerland. Its flagship service, the Augen-Check-Up, combines in-store measurements (visual acuity, refraction, intraocular pressure via tonometer, fundus photography) at optical retail locations with remote specialist interpretation, delivering a colour-coded traffic-light result within 48 hours. The platform powers three product modules: the standard Augen-Check-Up, Augen-Check-Up Plus (which adds anterior segment imaging), and the Ocumeda Care Network for structured referrals to local ophthalmologists.

The business model is primarily B2B2C, charging optician partners a per-screening fee for each Augen-Check-Up performed and earning enterprise platform fees from strategic partners Fielmann Group and ZEISS Vision Care (which also embedded Ocumeda as the medical layer of its ZEISS EyeCare Network). Revenue is supplemented by insurance reimbursement flows in Switzerland (KPT covers up to 75% of the cost for Pulse policyholders; CSS covers from 2023). The company serves consumer end-users (predominantly 40+ demographic) seeking accessible preventive eye screening, optical retail chains and independent opticians seeking a medically validated upsell service, and ophthalmologists who gain asynchronous review capacity.

Ocumeda operates through 800+ partner optician locations across the DACH region and has completed more than 500,000 screenings, detecting 110,000+ abnormalities and 3,500+ urgent cases. It is backed by Fielmann Group and ZEISS Vision Care (which acquired a 10% stake at a €100 million valuation in October 2025). The company holds ISO 13485 certification, is GDPR-compliant with ISO/IEC 27001 and BSI C5 cloud infrastructure, and is undergoing a €600,000 UKE Hamburg clinical validation study funded by Fielmann.

Ocumeda firmographics

Firmographics
Name
Ocumeda
Legal name
ocumeda GmbH
Website
https://ocumeda.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Ocumeda operates a cloud teleophthalmology platform connecting 800+ DACH partner opticians with 35+ remote ophthalmologists to deliver the Augen-Check-Up, a low-threshold preventive eye screening service powered by Fielmann and ZEISS distribution.
Ownership category
akta.pro rank

Ocumeda industry classification

Industry
Product category
Teleophthalmology / Preventive Eye Care Screening
NAICS
Offices of Optometrists (62132)
akta.pro industry
PRIMARYHLALAGAL
Ophthalmology & Vision Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLAKAKAB
Optometry Clinics (Primary Eye Care)

Keywords

  • Teleophthalmology platform
  • Preventive eye screening
  • Medical eye examinations
  • Retinal image analysis
  • Optical retail services

Where Ocumeda is headquartered

Location

Headquarters

HQ city
München
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

Ocumeda business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Per-Screening Fees (B2B to Opticians): Ocumeda charges optician partners (optical retail chains and independent stores) a fee for each Augen-Check-Up conducted using the Ocumeda platform. The screening data is collected by trained optician staff and transmitted to Ocumeda's tele-ophthalmologist network for interpretation. Revenue is generated on a per-transaction basis per screening performed.
  2. Insurance Reimbursement (Switzerland): In Switzerland, the Ocumeda Augen-Check-Up is covered by health insurance KPT for patients with Pulse Top or Pulse Premium supplementary insurance (up to 75% cost reimbursement). This creates a reimbursement revenue stream alongside the consumer self-pay model, reducing patient out-of-pocket cost.
  3. B2B Enterprise Platform Licensing: Ocumeda provides its teleophthalmology platform to enterprise customers such as ZEISS Vision Care (ZEISS EyeCare Network) and Fielmann Group, where Ocumeda acts as the underlying medical infrastructure. Revenue is derived from platform licensing and per-screening arrangements with these enterprise partners.
  4. Premium Screening Upgrades (Augen-Check-Up Plus): The extended Augen-Check-Up Plus (adding anterior eye segment imaging) represents an upsell opportunity over the standard screening, allowing opticians to offer a more comprehensive premium service at a higher price point.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goStandard Augen-Check-Up (KPT Reimbursement in Switzerland)
Transaction based/ take ratePay-as-you-goStandard Augen-Check-Up (Self-Pay / Optician-Sold)
Unit PricingPay-as-you-goAugen-Check-Up Plus (Extended Screening)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Ocumeda product offering

Product offering

Core offering

Ocumeda operates a cloud-based teleophthalmology platform that connects trained partner opticians with a network of certified remote ophthalmologists to deliver low-threshold preventive eye screenings. The core Augen-Check-Up service captures fundus photography, intraocular pressure, visual acuity and refraction data at optical retail locations and transmits it for physician interpretation, with results delivered to patients within 48 hours via a traffic-light reporting system. Extended offerings include anterior segment imaging (Augen-Check-Up Plus), structured ophthalmologist referrals (Care Network), and partner optician enablement (Empower).

Product overview

Ocumeda operates a modular teleophthalmology platform centered on the Augen-Check-Up, a preventive eye screening service that connects partner opticians with remote ophthalmologists. The core Augen-Check-Up performs fundus photography, intraocular pressure measurement, and visual acuity testing, evaluated by a network of 35 tele-ophthalmologists. Three add-on modules extend the platform: Augen-Check-Up Plus adds anterior segment imaging for a broader anatomical assessment; Ocumeda Care Network facilitates structured referrals to local ophthalmologists for patients with abnormal findings; and Ocumeda Empower provides training, marketing, and consulting to strengthen partner opticians' preventive care capabilities. The platform is available at over 800 partner optician locations across Germany, Austria, and Switzerland.

Differentiator

Problem solved

Functional benefit

Brands

  • Ocumeda Augen-Check-Up: The core teleophthalmological eye screening service offered at partner opticians, involving measurements of visual acuity, refraction, intraocular pressure, and fundus photography, analyzed by ophthalmologists.
  • Augen-Check-Up Plus
  • Ocumeda Care Network
  • Ocumeda Empower

Products and services

  • Augen-Check-Up (Eye Check-Up) The flagship teleophthalmology screening service that enables partner opticians to perform preventive eye health checks using fundus photography, intraocular pressure measurement, and visual acuity testing, with remote evaluation by licensed ophthalmologists from Germany, Austria, and Switzerland. Results are delivered to patients within 48 hours via a colour-coded traffic-light reporting system.
  • Augen-Check-Up Plus An enhanced version of the standard Augen-Check-Up that additionally captures and evaluates the anterior segment of the eye (eyelids, conjunctiva, cornea, iris, lens), enabling a broader medical screening alongside the existing fundus and intraocular pressure assessment.
  • Ocumeda Care Network A care coordination platform that connects eye check-up participants with abnormal findings to nearby ophthalmologists, enabling opticians to integrate local eye doctor partnerships into their service offering and facilitating structured patient referral and follow-up.
  • Ocumeda Empower A partner support program providing opticians with training (Ocumeda Academy), marketing assets, automated customer re-invitation tools, and consulting to help them establish and grow their preventive eye health service offering.
  • ZEISS EyeCare Network (Ocumeda-powered platform) White-label teleophthalmology platform embedded in the ZEISS EyeCare Network, connecting ZEISS partner opticians (using ZEISS VISUREF 1000 devices) with the Ocumeda tele-ophthalmologist network for preventive eye health checks.

Quantifiable outcome

  • Over 110,000 abnormalities detected from 500,000 screenings (~22% detection rate)
  • +4 more outcomes

Companies that use Ocumeda

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Ocumeda technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature7 records

Ocumeda partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • KPT (Swiss Health Insurance)coreStrategic or Co-development Partner · 8 April 2026KPT, one of the ten largest Swiss health insurers (~500,000 policyholders), added the Ocumeda Augen-Check-Up to its supplementary insurance (Pulse) benefit list under 'Früherkennung und Diagnostik'. Patients with Pulse Top or Pulse Premium coverage receive up to 75% cost reimbursement. Available at ~50 Ocumeda locations in Switzerland.
  • Universitätsklinikum Hamburg-Eppendorf (UKE)majorStrategic or Co-development Partner · 4 November 2025UKE is conducting a €600,000 medical study (funded by Fielmann Group) to scientifically validate the Ocumeda-based eye check-up screening service. The study compares screening results from Fielmann locations in Hamburg metropolitan area with comprehensive examinations at UKE. Results expected end of 2027. Led by Prof. Dr. Martin Spitzer, Director of the UKE Eye Clinic.
  • ZEISS Vision Care (ZEISS EyeCare Network)coreStrategic or Co-development Partner · 31 January 2025Ocumeda serves as the medical platform powering the ZEISS EyeCare Network. ZEISS Vision Care distributes Ocumeda's Augen-Check-Up to its partner opticians using ZEISS VISUREF 1000 devices. The platform connects optical retail stores with ophthalmologists for preventive eye health checks. Launched in Germany March 2025; Austria and Switzerland in H2 2025. Uses a traffic-light system to flag findings related to diabetic retinopathy, AMD and glaucoma.
  • Fielmann GroupcoreStrategic or Co-development Partner · 18 October 2023Strategic partnership to offer the Ocumeda Augen-Check-Up at Fielmann branches across Germany and Switzerland. Following a successful pilot phase, the service was rolled out to 100+ Fielmann locations by end of 2023, and has since expanded to all Fielmann branches in Germany, Austria and Switzerland. Over 300,000 Fielmann customers have used the service. Fielmann co-funded a €600,000 clinical validation study at UKE.
  • CSS Versicherung (Swiss Health Insurance)coreStrategic or Co-development Partner · 1 January 2023CSS, one of the largest Swiss health insurers, began covering Ocumeda Augen-Check-Up costs for its policyholders starting in 2023. This partnership made Ocumeda's screening service accessible through health insurance reimbursement in Switzerland, prior to the KPT partnership.
  • UnternehmerTUMminorOthersUnternehmerTUM, Germany's largest centre for business and innovation, is listed as a partner and supporter of Ocumeda. The nature of the partnership is not explicitly detailed beyond the logo placement on Ocumeda's website.
  • ACTO e.V. (Aachener Centrum für Technologietransfer in der Ophthalmologie)minorStrategic or Co-development PartnerOcumeda developed its concept in collaboration with ACTO e.V. and leading German ophthalmologists. ACTO co-authored the scientific whitepaper (Weißbuch) describing the clinical and scientific background of the Ocumeda Augen-Check-Up.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Ocumeda competitors and assessment

Company assessment

Emerging players

  • AEYE Health: Israel-based AI company developing FDA-cleared autonomous screening for diabetic retinopathy and other retinal diseases from fundus photography. Comparable to Ocumeda as a younger AI teleophthalmology competitor targeting optometry and primary care workflows.
  • RetinAI: Switzerland-based AI health-tech company building ophthalmology data management and AI image analysis tools (RetinAI Discovery, Discovery AIR) used by clinics and pharma. Comparable to Ocumeda as a fellow Swiss-based AI-ophthalmology player addressing disease detection from retinal imaging, though RetinAI is more B2B/research-oriented.

Broad incumbents

  • Heidelberg Engineering: Germany-based ophthalmic diagnostic imaging company (Heidelberg Retina Tomograph, SPECTRALIS OCT) widely used in clinical ophthalmology. Comparable as a domestic German incumbent in ophthalmic diagnostic imaging whose installed base represents both a potential integration partner and a potential competitor moving toward AI-enabled screening.
  • Optos (Nikon): UK-based (now part of Nikon) ultra-widefield retinal imaging company whose devices are deployed in optometry and ophthalmology practices globally. Comparable as an incumbent retinal imaging hardware vendor relevant to Ocumeda's screening workflow and as a potential vertical competitor in AI-enhanced screening.
  • Topcon Healthcare: Japan-headquartered global ophthalmic device and software company producing fundus cameras, OCT, and clinical data management systems used in teleophthalmology workflows. Comparable as a vertically integrated incumbent supplying both the imaging hardware (similar to ZEISS VISUREF 1000) and software infrastructure that Ocumeda integrates with.

Direct peers

  • Eyenuk: US-based developer of the EyeArt AI system for autonomous detection of diabetic retinopathy from fundus images, used in primary care and optometry settings. Closely comparable to Ocumeda's AI-assisted teleophthalmology screening model, though Eyenuk focuses on a single disease (DR) and US regulatory pathway (FDA-cleared).
  • Smart Optometry: Slovenia-based developer of mobile eye-screening applications used by optometrists and ophthalmologists for visual acuity, contrast, color vision and basic functional tests. Comparable as a peer in optometry-facing digital screening tools, though with a software/app-only model rather than a full teleophthalmology service.
  • Digital Diagnostics: US company (formerly IDx) that pioneered FDA-authorized autonomous AI diagnostic systems (IDx-DR) for diabetic retinopathy screening at point-of-care. Comparable as a direct AI teleophthalmology competitor with regulatory clearance and a similar optometry/primary-care distribution thesis.
  • Visibly: US-based online vision test platform enabling refractive prescription renewal via remote optometrist review. Comparable as a tele-optometry screening service routed through digital channels, though US-focused and oriented to prescription renewal rather than disease detection.

Regional players

  • Doctolib: France/Germany-headquartered leading European telehealth and practice-management platform with a strong German user base. Comparable as a broader European digital-health player operating in the same DACH regulatory and reimbursement environment, though Doctolib focuses on appointment booking and video consultations rather than teleophthalmology specifically.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Ocumeda social profiles

Digital presence

Ocumeda compliance and trust

Trust signal

Compliance3 records

Ocumeda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ocumeda leadership team

Management profile

Number of profiles

Profiles6 records

Ocumeda funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ocumeda M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocumeda

What does Ocumeda do?

Ocumeda operates a cloud-based teleophthalmology platform that connects trained partner opticians with a network of certified remote ophthalmologists to deliver low-threshold preventive eye screenings. The core Augen-Check-Up service captures fundus photography, intraocular pressure, visual acuity and refraction data at optical retail locations and transmits it for physician interpretation, with results delivered to patients within 48 hours via a traffic-light reporting system. Extended offerings include anterior segment imaging (Augen-Check-Up Plus), structured ophthalmologist referrals (Care Network), and partner optician enablement (Empower).

Is Ocumeda a public or private company?

Ocumeda is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ocumeda founded?

Ocumeda was founded in 2019. It employs 51 to 100 people.

Where is Ocumeda based?

Ocumeda is headquartered in München, Germany, in the Europe region.

How does Ocumeda make money?

Four revenue lines are on record. Per-Screening Fees (B2B to Opticians) is the primary driver. The others are insurance Reimbursement (Switzerland), B2B Enterprise Platform Licensing and premium Screening Upgrades (Augen-Check-Up Plus).

Who are Ocumeda's main competitors?

Emerging players on record are AEYE Health and RetinAI. Broad incumbents are Heidelberg Engineering, Optos (Nikon) and Topcon Healthcare. Direct peers are Eyenuk, Smart Optometry, Digital Diagnostics and Visibly. Doctolib is listed as a regional player.

Does Ocumeda have an API?

No public API is recorded for Ocumeda.

What industry is Ocumeda in?

Ocumeda's product category is Teleophthalmology / Preventive Eye Care Screening. Its primary akta.pro industry code is HLALAGAL, Ophthalmology & Vision Telemedicine Platforms, with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 62132.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
boerse.deFielmann-Gruppe fördert medizinische Studie des UKE zu innovativer Augenvorsorge im Großraum HamburgFielmann Group is sponsoring a €600,000 medical study by the University Hospital Hamburg-Eppendorf (UKE) to scientifically evaluate its eye check-up service, which uses tele-ophthalmology platform Ocumeda to deliver screening results via certified opticians. The study, led by Prof. Dr. Martin Spitzer, will compare Fielmann's screening results against comprehensive eye examinations at UKE for customers in the Hamburg metropolitan area, with results expected by end of 2027. Since launching in 2024, the service has already served 300,000 customers across Germany, Austria, and Switzerland, with 20% of cases flagging abnormalities requiring further examination.Investing.comZeiss Vision Care buys 10% stake in Ocumeda, plans to scale with Fielmann By Investing.comZeiss Vision Care acquired a 10% stake in Ocumeda AG, valuing the tele-ophthalmology platform at €100 million. The company plans to increase its ownership to up to 25% and scale the platform with Fielmann Group. The partnership aims to expand Ocumeda's market presence in vision care.ZEISSZEISS EyeCare Network – for Clear Vision and Healthy EyesZEISS Vision Care announced the world premiere of its ZEISS EyeCare Network on February 3, 2025, in Aalen, Germany, a platform connecting optical stores with ophthalmologists for preventive eye health checks using certified devices such as the ZEISS VISUREF 1000. The service will launch in Germany starting March 1, 2025, and in Austria and Switzerland in the second half of 2025, with Ocumeda as a partner to establish the network workflows for participating ZEISS customers. The platform uses a traffic light system to flag findings and aims to detect early changes related to diabetic retinopathy, age-related macular degeneration, and glaucoma.startupticker.chOcumeda obtains funds to build telemedicine network for eye careSwiss telemedicine company Ocumeda has secured CHF 150,000 in funding from Venture Kick to expand its cloud-based AI platform for eye care. The funds will be used to enhance services for connected ophthalmologists and roll out the screening service in Switzerland and Germany. This expansion aims to address significant access barriers to eye care in the DACH region.Venture KickOcumeda wins CHF 150,000 to build a telemedicine network providing easy access to eye careOcumeda has secured a CHF 150,000 Venture Kick award to expand its cloud-based telemedicine platform for eye care. The startup plans to use the funding to enhance offerings for connected ophthalmologists and roll out its eye screening service in Switzerland and Germany.